Neurocrine Biosciences, Inc.
Neurocrine Biosciences, Inc. Q2 FY26 Results — Earnings Call Analysis
Q2 FY26 earnings call: what management guided on revenue, margins and order book.
What the Q2 FY26 call signalled
2 of 4 strong
The short version
- INGREZZA reaffirmed 2026 sales guidance of $2.7 billion to $2.8 billion, expecting strong growth driven by double-digit volume increase and record new patient additions. - Neurocrine Biosciences expects record net product sales in 2026 driven by INGREZZA, CRENESSITY (annualizing over $600 million), and the pending addition of VYKAT XR.
From Neurocrine Biosciences, Inc.'s Q2 FY26 earnings-call transcript · updated 29 May 2026.
Revenue & Sales Performance
- INGREZZA reaffirmed 2026 sales guidance of $2.7 billion to $2.8 billion, expecting strong growth driven by double-digit volume increase and record new patient additions.
- CRENESSITY sales are annualizing at over $600 million, with steady new patient starts, strong persistency, broad prescriber adoption, and favorable reimbursement, positioning it as a potential blockbuster.
- Expanded sales force and ongoing commercial investments are expected to further accelerate CRENESSITY adoption and depth of prescribing.
- The pending acquisition of Soleno Therapeutics and addition of VYKAT XR will strengthen the commercial portfolio and contribute to growth.
2 more points from Neurocrine Biosciences, Inc.'s call on revenue
Pro opens every point from 15K+ earnings calls
Profitability & Margins
See what Neurocrine Biosciences, Inc. said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- No specific current or future capital expenditures (capex) or capital investment details were explicitly mentioned during the call.
- The company is focused on strategic business development aligned with its capital allocation priorities:
- Drive revenue growth
- Advance the pipeline
- Invest in business development
- Pending acquisition of Soleno Therapeutics and its product VYKAT XR expected to close in Q2, representing a strategic expansion to strengthen long-term growth.
- Continuing investment in R&D with plans to initiate 6 new Phase I and 4 new Phase II programs in 2026.
2 more points from Neurocrine Biosciences, Inc.'s call on capex
Pro opens every point from 15K+ earnings calls
Fundraising & Capital Structure
See what Neurocrine Biosciences, Inc. said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
2 more points from Neurocrine Biosciences, Inc.'s call on order book
Pro opens every point from 15K+ earnings calls
Continue your research
Others in Biotechnology this season
- Arrowhead Pharmaceuticals, Inc. (Q2 FY26)
Arrowhead Pharmaceuticals, Inc. Q2 FY26 quarterly results analysis. REDEMPLO launch momentum continues strong with prescriptions accelerating nearly threefold o
- Madrigal Pharmaceuticals, Inc. (Q2 FY26)
Madrigal Pharmaceuticals, Inc. Q2 FY26 quarterly results analysis. The company expects steady patient additions and robust net sales growth through 2026, with Q
- Exelixis, Inc. (Q2 FY26)
Exelixis, Inc. Q2 FY26 quarterly results analysis. CABOMETYX revenue and demand continue strong growth; Q1 2026 U.S. Market Cap $12,932, P/E 16.5. AI-powered ea
- Ionis Pharmaceuticals, Inc. (Q2 FY26)
Ionis Pharmaceuticals, Inc. Q2 FY26 quarterly results analysis. DAWNZERA sales expected at $110M-$120M in 2026, driven by switches from existing prophylactics a
Arthneeti Pro · Annual
Neurocrine Biosciences, Inc. and 15K+ more earnings calls,
for less than your morning chai
a day
Every earnings call, ranking and concall Q&A across all four results seasons.
Secure Razorpay payment · instant access
Frequently Asked Questions
What were Neurocrine Biosciences, Inc. Q2 FY26 results?
- INGREZZA reaffirmed 2026 sales guidance of $2.7 billion to $2.8 billion, expecting strong growth driven by double-digit volume increase and record new patient additions. - Neurocrine Biosciences expects record net product sales in 2026 driven by INGREZZA, CRENESSITY (annualizing over $600 million), and the pending addition of VYKAT XR.
What is Neurocrine Biosciences, Inc. share price analysis?
Neurocrine Biosciences, Inc. currently shows a below-average growth signal. The stock trades at a P/E of 24.0 with a market cap of $15,725. Investors should review the full earnings analysis for detailed insights.
Is Neurocrine Biosciences, Inc. planning capital expenditure?
- No specific current or future capital expenditures (capex) or capital investment details were explicitly mentioned during the call.
Keep Neurocrine Biosciences, Inc. on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.